LC-MS based stability-indicating method for studying the degradation of lonidamine under physical and chemical stress conditions

Ankit Kanaiyalal Rochani , Margaret Wheatley, Brian Edward Oeffinger, John Robert Eisenbrey, Gagan Kaushal

Abstract


Background and purpose: Lonidamine is a hexokinase II inhibitor, works as an anticancer molecule, and is extensively explored in clinical trials. Limited information prevails about the stability-indicating methods which could determine the forced degradation of lonidamine under stressed conditions. Hence, we report the use of a rapid, sensitive, reproducible, and highly accurate liquid chromatography and mass spectrometry method to analyze lonidamine degradation.

Experimental approach: The Xbridge BEH shield reverse phase C18 column (2.5 µm, 4.6 × 75 mm) using isocratic 50:50 water: acetonitrile with 0.1% formic acid can detect lonidamine with help of mass spectrometer in tandem with an ultraviolet (UV) detector at 260 nm wavelength. 

Findings/ Results: A linear curve with r² > 0.99 was obtained for tandem liquid chromatography-mass spectrometry (LC-MS)-UV based detections. This study demonstrated (in the present set up of isocratic elution) that LC-MS based detection has a relatively high sensitivity (S/N (10 ng/mL): 220 and S/N (20 ng/mL): 945) and accuracy at lower detection and quantitation levels, respectively. In addition to developing the LC-MS method, we also report that the current method is stability-indicating and shows that lonidamine gets degraded over time under all three stress conditions; acidic, basic, and oxidative.

Conclusion and implications: LC-MS based quantitation of lonidamine proved to be a better method compared to high-performance liquid chromatography (HPLC)-UV detections for mapping lonidamine degradation. This is the first report on the stability-indicating method for studying the forced degradation of lonidamine using LC-MS method..

Keywords


Forced degradation; LC-MS; Lonidamine; Stability indicating.

Full Text:

PDF

References


American Cancer Society, 2019. Available from: https://www.cancer.gov/about-cancer/understanding/statistics.

National Cancer Statistics, 2019. Available from: https://www.cancer.gov/about-cancer/understanding/statistics.

Semenza GL, Artemov D, Bedi A, Bhuwalla Z, Chiles K, Feldser D, et al. ‘The metabolism of tumours': 70 years later. Novartis Found Symp. 2001;240:251-260.

Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11): 891-899.

DOI: 10.1038/nrc1478.

Zhang Y, Yang JM. Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention. Cancer Biol Ther. 2013;14(2):81-89.

DOI: 10.4161/cbt.22958.

Kim JS, Ahn KJ, Kim JA, Kim HM, Lee JD, Lee JM, et al. Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells: ROS-mediated cell death by 3-BrPA. J Bioenerg Biomembr. 2008;40(6):607-618.

DOI: 10.1007/s10863-008-9188-0.

Liemburg-Apers DC, Willems PH, Koopman WJ, Grefte S. Interactions between mitochondrial reactive oxygen species and cellular glucose metabolism. Arch Toxicol. 2015;89(8):1209-1226.

DOI: 10.1007/s00204-015-1520-y.

da-Silva WS, Gomez-Puyou A, de Gomez-Puyou MT, Moreno-Sanchez R, De Felice FG, de Meis L, et al. Mitochondrial bound hexokinase activity as a preventive antioxidant defense: steady-state ADP formation as a regulatory mechanism of membrane potential and reactive oxygen species generation in mitochondria. J Biol Chem. 2004;279(38): 39846-39855.

DOI: 10.1074/jbc.M403835200.

Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25(34):4633-4646.

DOI: 10.1038/sj.onc.1209597.

Nath K, Guo L, Nancolas B, Nelson DS, Shestov AA, Lee SC, et al. Mechanism of antineoplastic activity of lonidamine. Biochim Biophys Acta. 2016;1866(2):151-162.

DOI: 10.1016/j.bbcan.2016.08.001.

Cervantes-Madrid D, Romero Y, Duenas-Gonzalez A. Reviving lonidamine and 6-Diazo-5-oxo-L-norleucine to be used in combination for metabolic cancer therapy. Biomed Res Int. 2015;2015:690492,1-13.

DOI: 10.1155/2015/690492.

Nath K, Guo L, Nancolas B, Nelson DS, Shestov AA, Lee SC, et al. Mechanism of antineoplastic activity of lonidamine. Biochim Biophys Acta. 2016;1866(2):151-162.

DOI: 10.1016/j.bbcan.2016.08.001.

Nath K, Nelson DS, Ho AM, Lee SC, Darpolor MM, Pickup S, et al. (31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan. NMR Biomed. 2013;26(1):98-105.

DOI: 10.1002/nbm.2824.

Nath K, Nelson DS, Heitjan D, Leeper DB, Zhou R, Glickson JD. Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin. NMR Biomed. 2015;28(3):281-290.

DOI: 10.1002/nbm.3240.

De Lena M, Lorusso V, Latorre A, Fanizza G, Gargano G, Caporusso L, et al. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur J Cancer. 2001;37(3):364-368.

DOI: 10.1016/s0959-8049(00)00400-7.

Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25(34):4633-4646.

DOI: 10.1038/sj.onc.1209597.

Zhang BF, Xing L, Qiao JB, Cui PF, Wang FZ, Zhang JL, et al. In vivo synergistic antitumor effect and safety of siRNA and lonidamine dual-loaded hierarchical targeted nanoparticles. Int J Pharm. 2016;506(1-2):207-213.

DOI: 10.1016/j.ijpharm.2016.04.056.

Ruttala HB, Ramasamy T, Poudel BK, Ruttala RRT, Jin SG, Choi HG, et al. Multi-responsive albumin-lonidamine conjugated hybridized gold nanoparticle as a combined photothermal-chemotherapy for synergistic tumor ablation. Acta Biomater. 2020;101:531-543.

DOI: 10.1016/j.actbio.2019.11.003.

Grippa E, Gatto MT, Leone MG, Tita B, Adbel-Haq H, Vitalone A, et al. Analysis of lonidamine in rat serum and testis by high performance liquid chromatography. Biomed Chromatogr. 2001;15(1):1-8.

DOI: 10.1002/bmc.14.

Chen BQ, Kankala RK, Wang SB, Chen AZ. Continous nanonization of lonidamine by modified-rapid expansion of supercritical solution process. J of Superitical fluids. 2018;133(1):486-493.

DOI: 10.1016/j.supflu.2017.11.016.

Ioele G, De Luca M, Ragno G. Lonidamine and related impurities: HPLC analysis, stability profile and degradation pathways. Anal Methods. 2013;5(7):1715-1720.

DOI: 10.1039/C3AY26467J.

Milane L, Duan ZF, Amiji M. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. Nanomedicine. 2011;7(4):435-444.

DOI: 10.1016/j.nano.2010.12.009.

Lam E, Rochani A, Kaushal G, Thoma BN, Tanjuakio J, West FM, et al. Pharmacokinetics of ketamine at dissociative doses in an adult patient with refractory status asthmaticus receiving extracorporeal membrane oxygenation therapy. Clin Ther. 2019;41(5):994-999.

DOI: 10.1016/j.clinthera.2019.03.005.

Rochani A, Lam E, Tanjuakio J, Hirose H, Kraft WK, Kaushal G. Simultaneous quantitative LC-MS method of ketamine, midazolam and their metabolites (dehydronorketamine, norketamine and 1hydroxymidazolam) for its application in patients on extracorporeal membrane oxygenation (ECMO) therapy. J Pharm Biomed Anal. 2020;178:112947,1-9.

DOI: 10.1016/j.jpba.2019.112947.

US Department of Health and Human Services, FDA, CDER, CVM. Bioanalytical Method Validation Guidance for Industry. 2018. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry.

Moorthy GS, Jogiraju H, Vedar C, Zuppa AF. Development and validation of a sensitive assay for analysis of midazolam, free and conjugated 1-hydroxymidazolam and 4-hydroxymidazolam in pediatric plasma: application to pediatric pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1067:1-9.

DOI: 10.1016/j.jchromb.2017.09.030.

Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs-a review. J Pharm Anal. 2014;4(3):159-165.

DOI: 10.1016/j.jpha.2013.09.003.

Mohammadi A, Rezanour N, Ansari Dogaheh M, Ghorbani Bidkorbeh F, Hashem M, Walker RB. A stability-indicating high performance liquid chromatographic (HPLC) assay for the simultaneous determination of atorvastatin and amlodipine in commercial tablets. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;846(1-2):215-221.

DOI: 10.1016/j.jchromb.2006.09.007.

Duraisamy K, Jaganathan KS, Krishna MV. Method development and validation of HPLC tandem/mass spectrometry for quantification of perindopril arginine and amlodipine besylate combination in bulk and pharmaceutical formulations. Res Pharm Sci. 2017;12(4):307-314.

DOI: 10.4103/1735-5362.212048.

Rezazadeh M, Emami J. A simple and sensitive HPLC method for analysis of imipramine in human plasma with UV detection and liquid-liquid extraction: application in bioequivalence studies. Res Pharm Sci. 2016;11(2):168-176.

Varshosaz J, Emami J, Tavakoli N, Minaiyan M, Rahmani N, Ahmadi F, et al. Development and validation of a rapid HPLC method for simultaneous analysis of budesonide and its novel synthesized hemiesters in colon specific formulations. Res Pharm Sci. 2011;6(2):107-116.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.